Roche Holding AG, the world’s leader in oncology drugs, struck an upbeat tone about approval prospects for its key drug Avastin in ovarian cancer ahead of an important industry meeting next month.
The group’s pharma head Pascal Soriot told reporters on Thursday he was confident Avastin will gain European approval and he was also relatively optimistic about winning U.S. backing for the drug.
